BRPI0409434A - formulações farmacêuticas nasais e métodos para usar as mesmas - Google Patents

formulações farmacêuticas nasais e métodos para usar as mesmas

Info

Publication number
BRPI0409434A
BRPI0409434A BRPI0409434-4A BRPI0409434A BRPI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A BR PI0409434 A BRPI0409434 A BR PI0409434A
Authority
BR
Brazil
Prior art keywords
pharmaceutical formulations
drug substance
methods
formulations
nasal pharmaceutical
Prior art date
Application number
BRPI0409434-4A
Other languages
English (en)
Inventor
Imtiaz Chaudry
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0409434A publication Critical patent/BRPI0409434A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/02—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using physical processes
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

"FORMULAçõES FARMACêUTICAS NASAIS E MéTODOS PARA USAR AS MESMAS". A presente invenção refere-se a formulações farmacêuticas nasais descritas no presente relatório, que compreendem uma substância de droga com um perfil de distribuição de tamanhos de partículas específico. Esse perfil proporciona maior biodisponibilidade, maior eficácia ou efeito terapêutico prolongado da substância de droga quando administrada por via intranasal. As formulações da presente invenção podem compreender um ou mais corticoesteróides com um perfil de distribuição de tamanhos de partículas específico. Em uma modalidade preferida, o corticoesteróide é fluticasona ou um derivado farmaceuticamente aceitável da mesma para o tratamento de um ou mais sintomas de rinite. Preferivelmente, a substância de droga é propionato de fluticasona. As formulações do presente relatório podem ser administradas como uma suspensão aquosa apropriada para inalação por meio da via nasal.
BRPI0409434-4A 2003-04-16 2004-03-29 formulações farmacêuticas nasais e métodos para usar as mesmas BRPI0409434A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/414,756 US7811606B2 (en) 2003-04-16 2003-04-16 Nasal pharmaceutical formulations and methods of using the same
PCT/EP2004/003315 WO2004091575A1 (en) 2003-04-16 2004-03-29 Nasal pharmaceutical formulations and methods of using the same

Publications (1)

Publication Number Publication Date
BRPI0409434A true BRPI0409434A (pt) 2006-04-18

Family

ID=33158765

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0409434-4A BRPI0409434A (pt) 2003-04-16 2004-03-29 formulações farmacêuticas nasais e métodos para usar as mesmas

Country Status (13)

Country Link
US (3) US7811606B2 (pt)
EP (1) EP1613281B1 (pt)
JP (1) JP5403868B2 (pt)
KR (1) KR101312331B1 (pt)
CN (1) CN1805729B (pt)
AU (1) AU2004229148B8 (pt)
BR (1) BRPI0409434A (pt)
CA (1) CA2522291C (pt)
ES (1) ES2609910T3 (pt)
MX (1) MXPA05011105A (pt)
RU (1) RU2373925C2 (pt)
WO (1) WO2004091575A1 (pt)
ZA (1) ZA200509238B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2518960C (en) * 2003-03-14 2013-08-27 Sinexus, Inc. Sinus delivery of sustained release therapeutics
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US8912174B2 (en) 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
KR100675379B1 (ko) * 2005-01-25 2007-01-29 삼성전자주식회사 프린팅 시스템 및 프린팅 방법
EP2298317A1 (en) 2005-04-04 2011-03-23 Sinexus, Inc. Device and methods for treating paranasal sinus conditions
US8535707B2 (en) * 2006-07-10 2013-09-17 Intersect Ent, Inc. Devices and methods for delivering active agents to the osteomeatal complex
US20090198179A1 (en) 2007-12-18 2009-08-06 Abbate Anthony J Delivery devices and methods
WO2010014834A1 (en) 2008-08-01 2010-02-04 Sinexus, Inc. Methods and devices for crimping self-expanding devices
US7863074B2 (en) * 2008-09-30 2011-01-04 Stion Corporation Patterning electrode materials free from berm structures for thin film photovoltaic cells
AU2010248992B2 (en) * 2009-05-15 2014-11-27 Intersect Ent, Inc. Expandable devices and methods therefor
ES2612257T3 (es) * 2011-05-03 2017-05-16 Chiesi Farmaceutici S.P.A. Formulación de suspensión mejorada de dipropionato de beclometasona para administración mediante inhalación
CN103501765B (zh) * 2011-05-04 2015-06-17 奇斯药制品公司 含有皮质类固醇作为活性成分的局部制剂
WO2014151963A2 (en) 2013-03-14 2014-09-25 Intersect Ent, Inc. Systems, devices, and method for treating a sinus condition
US11554229B2 (en) 2013-03-26 2023-01-17 OptiNose Inc. Nasal administration
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
AU2016209105B2 (en) 2015-01-22 2020-05-14 Intersect Ent, Inc. Drug-coated balloon
CN104940994B (zh) * 2015-07-14 2017-09-19 江苏威克斯医疗科技有限公司 一种人造鼻粘膜及其用途
CN107320449B (zh) * 2017-08-07 2020-09-15 武汉武药科技有限公司 丙酸氟替卡松鼻喷雾剂及其制备方法
US12403291B2 (en) 2019-08-30 2025-09-02 Intersect Ent, Inc. Submucosal bioresorbable drug eluting platform

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3091569A (en) 1960-08-26 1963-05-28 Mead Johnson & Co Mucolytic-nu-acylated sulfhydryl compositions and process for treating animal mucus
GB8432063D0 (en) * 1984-12-19 1985-01-30 Riker Laboratories Inc Physically modified steroids
EP0579260A1 (en) 1987-07-07 1994-01-19 Beecham Group Plc Use of a vasodilator for the treatment of pulmonary hypertension and/or right heart failure-related conditions
AU610175B2 (en) 1988-05-25 1991-05-16 Biogal Gyogyszergyar Pharmaceutical composition comprising a compound containing sulfhydryl group(s) for the treatment of otitis
CA2010894A1 (en) 1989-02-28 1990-08-31 Isamu Horikoshi Method of forming a suspension and composition formed by said method
JPH03165833A (ja) * 1989-02-28 1991-07-17 Isamu Horikoshi 新規懸濁化方法及びこの方法によって得られる組成物
SE9000207L (sv) 1990-01-22 1991-07-23 Nobel Chemicals Ab Laekemedel samt anvaendningen av detsamma
HU213401B (en) 1990-09-10 1997-06-30 Schering Corp Process for producing mometasone furoate monohydrate and pharmaceutical composition containing it
US5177447A (en) * 1990-11-06 1993-01-05 Bear Automotive Service Equipment Company Automated breakout box for automotive testing
US5174475A (en) 1991-03-26 1992-12-29 Glaxo Inc. Sequential dosing of antifungal and antiinflammatory compositions
US5593688A (en) 1993-06-25 1997-01-14 Nexstar Pharmaceuticals, Inc. Liposomal targeting of ischemic tissue
JPH0753358A (ja) 1993-08-17 1995-02-28 Teijin Ltd 吸入剤
GB9410222D0 (en) 1994-05-21 1994-07-06 Glaxo Wellcome Australia Ltd Medicaments
US6113894A (en) 1995-01-23 2000-09-05 Smith; S. Gregory Ophthalmic compositions and process of using
IT1275955B1 (it) 1995-03-22 1997-10-24 Dompe Spa Formulazioni farmaceutiche in forma di gel tissotropico
CA2231050A1 (en) 1995-09-07 1997-03-13 Biovail International Ltd. System for rendering substantially non-dissoluble bio-affecting agents bio-available
US5795909A (en) 1996-05-22 1998-08-18 Neuromedica, Inc. DHA-pharmaceutical agent conjugates of taxanes
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
US5976573A (en) 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
TW416953B (en) 1996-09-25 2001-01-01 Takeda Chemical Industries Ltd Tricyclic compounds for eliciting a prostaglandin I2 receptor agonistic effect, their production and use
FR2756739B1 (fr) 1996-12-05 2000-04-28 Astra Ab Nouvelle formulation de budesonide
TW503113B (en) 1997-01-16 2002-09-21 Senju Pharma Co Aqueous suspension for nasal administration
WO1999018971A1 (en) 1997-10-09 1999-04-22 Schering Corporation Mometasone furoate suspensions for nebulization
DE69838338T2 (de) 1997-10-22 2008-05-21 Jens Rochester Ponikau Verwendung von antimykotica zur topischen behandlung von pilz-induzierten schleimhautentzündungen
JP3386349B2 (ja) 1997-10-30 2003-03-17 帝人株式会社 水性懸濁医薬品組成物
SE9704186D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6423423B2 (en) 1998-05-06 2002-07-23 Calsonic Kansei Corporation Formed strip and roll forming
US6241969B1 (en) 1998-06-26 2001-06-05 Elan Corporation Plc Aqueous compositions containing corticosteroids for nasal and pulmonary delivery
EP1108423B1 (en) 1998-08-26 2005-03-30 Teijin Limited Powdery pernasal compositions
IT1303692B1 (it) * 1998-11-03 2001-02-23 Chiesi Farma Spa Procedimento per la preparazione di sospensioni di particelle difarmaci da somministrare per inalazione.
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US20040141925A1 (en) 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
US6521212B1 (en) 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
DE60018881T2 (de) 1999-06-03 2006-02-16 Johnson & Johnson Consumer France Sas Extrakte von mutterkraut (tanacetum parthenium) gegen entzündliche erkrankungen
JP2001002589A (ja) * 1999-06-18 2001-01-09 Teijin Ltd 穏やかな薬物血中濃度の上昇を可能とする経鼻投与用組成物
US20020061281A1 (en) 1999-07-06 2002-05-23 Osbakken Robert S. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
AU6076200A (en) 1999-07-08 2001-01-30 Johnson & Johnson Consumer Companies, Inc. Exothermic bandage
GB9918559D0 (en) 1999-08-07 1999-10-06 Glaxo Wellcome Kk Novel pharmaceutical formulation
WO2001013885A1 (en) 1999-08-20 2001-03-01 Norton Healthcare Ltd. Method to produce powders for pulmonary or nasal administration
GB9925934D0 (en) 1999-11-03 1999-12-29 Glaxo Group Ltd Novel apparatus and process
FI20002217A7 (fi) 1999-12-30 2001-07-01 Orion Yhtymae Oyj Inhalaatiopartikkelit
GB0009605D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Medicaments
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
GB0016040D0 (en) 2000-06-29 2000-08-23 Glaxo Group Ltd Novel process for preparing crystalline particles
DK2153819T3 (da) 2000-07-14 2012-12-03 Allergan Inc Anvendelse af en opløselighedsforbedrende bestanddel i en vandig sammensætning omfattende brimonidintartrat
US6608054B2 (en) 2001-03-20 2003-08-19 Boehringer Ingelheim Pharma Kg Pharmaceutical compositions based on anticholinergics and endothelin antagonists
AU2002241538A1 (en) 2000-12-01 2002-07-24 Nephros Therapeutics, Inc. Intrasvascular drug delivery device and use therefor
DE10060890C2 (de) 2000-12-07 2003-04-03 Meta Motoren Energietech Vorrichtung zum Umschalten des Betriebs eines Ladungswechselventils einer Brennkraftmaschine
EP1365739A1 (en) * 2001-02-05 2003-12-03 Pharmacia & Upjohn Company Composition for rectal delivery of an oxazolidinone antibacterial drug
GB0105560D0 (en) 2001-03-07 2001-04-25 Glaxo Group Ltd Pharmaceutical formulations
EP1427407A4 (en) 2001-03-23 2005-05-11 Luitpold Pharm Inc FAT AMIN DRUG CONJUGATES
ES2387562T3 (es) 2001-03-23 2012-09-26 Luitpold Pharmaceuticals, Inc. Conjugados alcohol graso-medicamento
US20020198209A1 (en) 2001-05-03 2002-12-26 Allergan Sales Inc. Compositions having enhanced pharmacokinetic characteristics
WO2003013434A2 (en) 2001-08-06 2003-02-20 Genomed, Llc Methods and compositions for treating diseases associated with excesses in ace
FR2831446B1 (fr) 2001-10-26 2004-03-05 Sanofi Synthelabo Utilisation de l'irbesartan pour la preparation de medicaments utiles pour la prevention ou le traitement de l'hypertension pulmonaire
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
US9808471B2 (en) * 2003-04-16 2017-11-07 Mylan Specialty Lp Nasal pharmaceutical formulations and methods of using the same
US7811606B2 (en) * 2003-04-16 2010-10-12 Dey, L.P. Nasal pharmaceutical formulations and methods of using the same

Also Published As

Publication number Publication date
CN1805729B (zh) 2010-09-22
HK1091727A1 (en) 2007-01-26
US20040208831A1 (en) 2004-10-21
WO2004091575A1 (en) 2004-10-28
AU2004229148B2 (en) 2010-11-25
MXPA05011105A (es) 2006-05-19
RU2373925C2 (ru) 2009-11-27
CA2522291A1 (en) 2004-10-28
US20080058295A1 (en) 2008-03-06
US8158154B2 (en) 2012-04-17
EP1613281A1 (en) 2006-01-11
KR20060003009A (ko) 2006-01-09
KR101312331B1 (ko) 2013-09-27
AU2004229148A1 (en) 2004-10-28
JP2006523629A (ja) 2006-10-19
ZA200509238B (en) 2007-04-25
AU2004229148B8 (en) 2010-12-02
JP5403868B2 (ja) 2014-01-29
US20060039871A1 (en) 2006-02-23
CN1805729A (zh) 2006-07-19
ES2609910T3 (es) 2017-04-25
EP1613281B1 (en) 2016-10-05
US7811606B2 (en) 2010-10-12
CA2522291C (en) 2011-12-06
US7972627B2 (en) 2011-07-05
RU2005135332A (ru) 2006-08-10

Similar Documents

Publication Publication Date Title
BRPI0409434A (pt) formulações farmacêuticas nasais e métodos para usar as mesmas
BRPI0409381A (pt) formulações farmacêuticas nasais e métodos de utilizar as mesmas
Pires et al. Intranasal drug delivery: how, why and what for?
ES2876350T3 (es) Métodos para aumentar la inhibición tónica y tratamiento del insomnio secundario
US6297227B1 (en) Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
BR0312128A (pt) Formulação, produto farmacêutico, embalagem de pressão. mdi, pulverizador nasal, processos para preparar um produto farmacêutico e uma formulação e métodos para profilaxia ou tratamento em um mamìfero tal como um humano, de condições para as quais a administração de um ou mais anti-histamìnico e/ou um ou mais esteróides é indicada e para tratamento de irritação do distúrbios do nariz ou do olho e de distúrbios das vias aéreas
BRPI0507609A (pt) combinações terapêuticas de anti-psicóticos atìpicos com antagonistas de fator de liberação de corticotropina
WO2006122318A3 (en) Directed intranasal administration of pharmaceutical agents
Alkotaji Azithromycin and ambroxol as potential pharmacotherapy for SARS-CoV-2
Andrade Intranasal drug delivery in neuropsychiatry: focus on intranasal ketamine for refractory depression
CA2474479A1 (en) Composition for inhalation
JP2019530751A (ja) 神経変性疾患を処置するためのカンナビノイド含有複合混合物
BRPI0517481A (pt) método para tratar, controlar ou evitar uma doença ou distúrbio parasìtico protozoário, e, composição farmacêutica
BR112015009504A2 (pt) inibidores de rock
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
BRPI0304821B8 (pt) processo de preparação de uma suspensão estéril de partículas de corticosteróide para administração por inalação
PT1256339E (pt) Sistema terapeutico transdermico para doenca de parkinson que induz niveis plasmaticos altos de rotigotina
CA2671470A1 (en) Powder formulation for valganciclovir
BRPI0508170A (pt) formulações farmacêuticas para inaladores de pó seco, que compreendem um ingrediente ativo de potência de baixa dosagem
MY159377A (en) Aqueous suspensions of ciclesonide for nebulisation
WO2005044186A3 (en) Inhalable pharmaceutical formulations employing desiccating agents and methods of administering the same
BRPI0519030A2 (pt) mÉtodos de tratamento, prevenÇço, ou controle de inflamaÇço das vias aÉreas e de uma doenÇa ou distérbio das vias aÉreas ou pulmonar, e, composiÇço farmacÊutica
EP4151210A3 (en) Pyridine-carboline derivatives as mchr1 antagonists for use in therapy
ATE326947T1 (de) Thixotropes nasenspray
WO2021202992A3 (en) Rapid point of care assay for the detection of the asymptomatic carrier state of covid-19

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B25A Requested transfer of rights approved

Owner name: MYLAN, INC. (US)

B25A Requested transfer of rights approved

Owner name: MYLAN SPECIALITY L.P. (US)